| 1 |
Zhou_2020 |
Network-based Drug Repurposing for Human Coronavirus |
Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng |
2020 |
2020-02-05 |
BioRxiv |
Y |
|
|
10.1101/2020.02.03.20020263 |
b4mdiont |
0.824134 |
|
Zhou_2020 |
| 2 |
Zhou_2020 |
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
Zhou, Yadi; Hou, Yuan; Shen, Jiayu; Huang, Yin; Martin, William; Cheng, Feixiong |
2020 |
2020-03-16 |
COMM-USE |
Y |
PMC7073332 |
32194980.0 |
10.1038/s41421-020-0153-3 |
4yuw7jo3 |
0.820443 |
|
Zhou_2020 |
| 3 |
Elfiky_2020 |
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study |
Elfiky, Abdo A. |
2020 |
2020-03-25 |
PMC |
Y |
|
|
10.1016/j.lfs.2020.117592 |
3pxc5wot |
0.736241 |
|
|
| 4 |
Beck_2020 |
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model |
Bo Ram Beck; Bonggun Shin; Yoonjung Choi; Sungsoo Park; Keunsoo Kang |
2020 |
2020-02-02 |
BioRxiv |
Y |
|
|
10.1101/2020.01.31.929547 |
cszqykpu |
0.728328 |
Shaw_2011 |
Beck_2020, Li_Y_2020, Tang_2020, Zhu_X_2015 |
| 5 |
Beck_2020 |
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model |
Beck, Bo Ram; Shin, Bonggun; Choi, Yoonjung; Park, Sungsoo; Kang, Keunsoo |
2020 |
2020-03-30 |
PMC |
Y |
|
|
10.1016/j.csbj.2020.03.025 |
zb434ve3 |
0.728328 |
|
Tang_2020, Beck_2020 |
| 6 |
Hall_2020 |
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |
Hall, Donald C.; Ji, Hai-Feng |
2020 |
2020-04-12 |
PMC |
Y |
|
|
10.1016/j.tmaid.2020.101646 |
pgxew3yk |
0.713641 |
Ekins_2015, Beigel_2010 |
|
| 7 |
Liao_2020 |
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies |
Liao, Jiayu; Way, George; Madahar, Vipul |
2020 |
2020-03-31 |
PMC |
Y |
|
|
10.1016/j.medidd.2020.100037 |
vijzfbyj |
0.692065 |
Dove_2004 |
Rut_W_2020 |
| 8 |
Gao_K_2020 |
Machine intelligence design of 2019-nCoV drugs |
Kaifu Gao; Duc Duy Nguyen; Rui Wang; Guo-Wei Wei |
2020 |
2020-02-04 |
BioRxiv |
Y |
|
|
10.1101/2020.01.30.927889 |
1qniriu0 |
0.677305 |
|
Li_Y_2020, Zhu_X_2015, Yamamoto_2004 |
| 9 |
Yamamoto_2020 |
Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. |
Norio Yamamoto; Shutoku Matsuyama; Tyuji Hoshino; Naoki Yamamoto |
2020 |
2020-04-08 |
BioRxiv |
Y |
|
|
10.1101/2020.04.06.026476 |
662pfa61 |
0.672904 |
Yamamoto_2004, Vardanyan_2016 |
Yamamoto_2004 |
| 10 |
Bleasel_2020 |
Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses |
Bleasel, Martin D.; Peterson, Gregory M. |
2020 |
2020-03-21 |
COMM-USE |
Y |
PMC7151655 |
32245264.0 |
10.3390/ph13030051 |
2kw2rtz3 |
0.601684 |
Shaw_2011 |
|
| 11 |
Adedeji_2014 |
Antiviral drugs specific for coronaviruses in preclinical development |
Adedeji, Adeyemi O; Sarafianos, Stefan G |
2014 |
2014-10-31 |
None |
N |
PMC4195804 |
24997250.0 |
10.1016/j.coviro.2014.06.002 |
0j8rvapz |
0.583767 |
|
Haagmans_2006 |
| 12 |
Wang_2020 |
Genetic Profiles in Pharmacogenes Indicate Personalized Drug Therapy for COVID-19 |
Lei-Yun Wang; Jia-Jia Cui; Qian-Ying OuYang; Yan Zhan; Yi-Min Wang; Xiang-Yang Xu; Cheng-Xian Guo; JiYe Yin |
2020 |
2020-03-30 |
BioRxiv |
Y |
|
|
10.1101/2020.03.23.20041350 |
xvba5mqq |
0.563608 |
|
Xing_2020 |
| 13 |
Baron_2020 |
Teicoplanin: an alternative drug for the treatment of COVID-19? |
Baron, Sophie Alexandra; Devaux, Christian; Colson, Philippe; Raoult, Didier; Rolain, Jean-Marc |
2020 |
2020-03-13 |
PMC |
Y |
|
|
10.1016/j.ijantimicag.2020.105944 |
yf5g53a9 |
0.560400 |
|
Wu_H_2016 |
| 14 |
Cheng_2015 |
Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus |
Cheng, Kai-Wen; Cheng, Shu-Chun; Chen, Wei-Yi; Lin, Min-Han; Chuang, Shang-Ju; Cheng, I-Hsin; Sun, Chiao-Yin; Chou, Chi-Yuan |
2015 |
2015-03-31 |
PMC |
N |
PMC7113672 |
25542975.0 |
10.1016/j.antiviral.2014.12.011 |
zj34cb6f |
0.553206 |
|
|
| 15 |
Li_Z_2020 |
FEP-based screening prompts drug repositioning against COVID-19 |
Zhe Li; Xin Li; Yi-You Huang; Yaoxing Wu; Lingli Zhou; Runduo Liu; Deyan Wu; Lei Zhang; Hao Liu; Ximing Xu; Yuxia Zhang; Jun Cui; Xin Wang; Hai-Bin Luo |
2020 |
2020-03-25 |
BioRxiv |
Y |
|
|
10.1101/2020.03.23.004580 |
xjr93dm6 |
0.514919 |
Shaw_2011, Pizzorno_2019 |
Zhu_X_2015, Rut_W_2020, Adhikari_2017 |
| 16 |
Cinatl_Jr_2005 |
Role of interferons in the treatment of severe acute respiratory syndrome |
Cinatl Jr, Jindrich; Michaelis, Martin; Scholz, Martin; Doerr, Hans Wilhelm |
2005 |
2005-02-23 |
PMC |
N |
PMC7103669 |
15174965.0 |
10.1517/14712598.4.6.827 |
kajs07ms |
0.485810 |
|
|
| 17 |
Cao_Y_2020 |
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence |
Cao, Yu-chen; Deng, Qi-xin; Dai, Shi-xue |
2020 |
2020-04-02 |
PMC |
Y |
|
|
10.1016/j.tmaid.2020.101647 |
b518n9dx |
0.438753 |
Beigel_2010 |
|
| 18 |
Adhikari_2017 |
Chapter 11 Structural Insight Into the Viral 3C-Like Protease Inhibitors: Comparative SAR/QSAR Approaches |
Adhikari, Nilanjan; Baidya, Sandip K.; Saha, Achintya; Jha, Tarun |
2017 |
2017-12-31 |
PMC |
N |
PMC7150231 |
|
10.1016/b978-0-12-809712-0.00011-3 |
z6v6s46n |
0.435794 |
|
Rut_W_2020, Zhou_2011 |
| 19 |
Alakwaa_2020 |
Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |
Alakwaa, Fadhl M. |
2020 |
2020-04-14 |
COMM-USE |
Y |
PMC7159901 |
32291351.0 |
10.1128/msystems.00297-20 |
j4u4fbba |
0.430439 |
Dove_2004 |
|
| 20 |
Amanat_2020 |
SARS-CoV-2 Vaccines: Status Report |
Amanat, Fatima; Krammer, Florian |
2020 |
2020-04-06 |
PMC |
Y |
|
|
10.1016/j.immuni.2020.03.007 |
m5ho8jqp |
0.418257 |
|
|
| 21 |
Ekins_2020 |
Déjà vu: Stimulating open drug discovery for SARS-CoV-2 |
Ekins, Sean; Mottin, Melina; Ramos, Paulo R.P.S.; Sousa, Bruna K.P.; Neves, Bruno Junior; Foil, Daniel H.; Zorn, Kimberley M.; Braga, Rodolpho C.; Coffee, Megan; Southan, Christopher; Puhl, Ana C.; Andrade, Carolina Horta |
2020 |
2020-04-19 |
PMC |
Y |
|
|
10.1016/j.drudis.2020.03.019 |
mwf0fjua |
0.405072 |
|
|
| 22 |
Jeon_2020 |
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs |
Sangeun Jeon; Meehyun Ko; Jihye Lee; Inhee Choi; Soo Young Byun; Soonju Park; David Shum; Seungtaek Kim |
2020 |
2020-03-20 |
BioRxiv |
Y |
|
|
10.1101/2020.03.20.999730 |
5f95gve3 |
0.394800 |
Beigel_2010, Dove_2004, Ekins_2015, García-Serradilla_2019 |
Zhou_2011, Tan_E_2004 |
| 23 |
Zhang_2005 |
Generation of predictive pharmacophore model for SARS-coronavirus main proteinase |
Zhang, Xue Wu; Yap, Yee Leng; Altmeyer, Ralf M. |
2005 |
2005-01-31 |
PMC |
N |
PMC7115589 |
15642409.0 |
10.1016/j.ejmech.2004.09.013 |
1v110xgs |
0.388028 |
Park_2012 |
|
| 24 |
Zhang_2020 |
Current status of potential therapeutic candidates for the COVID-19 crisis |
Zhang, Jiancheng; Xie, Bing; Hashimoto, Kenji |
2020 |
2020-04-22 |
PMC |
Y |
|
|
10.1016/j.bbi.2020.04.046 |
4zmqplz0 |
0.386805 |
Dove_2004, Beigel_2010 |
|
| 25 |
Lythgoe_2020 |
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic |
Lythgoe, Mark P.; Middleton, Paul |
2020 |
2020-04-09 |
PMC |
Y |
|
|
10.1016/j.tips.2020.03.006 |
52f5pdw2 |
0.384794 |
Dove_2004 |
|
| 26 |
Kilianski_2014 |
Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors |
Kilianski, Andy; Baker, Susan C. |
2014 |
2014-01-31 |
None |
N |
PMC3931262 |
24269477.0 |
10.1016/j.antiviral.2013.11.004 |
y3zrt52j |
0.384695 |
|
Xiong_2020, Adedeji_2014 |
| 27 |
Yamamoto_2004 |
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus |
Yamamoto, Norio; Yang, Rongge; Yoshinaka, Yoshiyuki; Amari, Shinji; Nakano, Tatsuya; Cinatl, Jindrich; Rabenau, Holger; Doerr, Hans Wilhelm; Hunsmann, Gerhard; Otaka, Akira; Tamamura, Hirokazu; Fujii, Nobutaka; Yamamoto, Naoki |
2004 |
2004-06-04 |
PMC |
Y |
PMC7111005 |
15144898.0 |
10.1016/j.bbrc.2004.04.083 |
77cylm1o |
0.383933 |
|
Tan_E_2004 |
| 28 |
Rossignol_2016 |
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus |
Rossignol, Jean-François |
2016 |
2016-06-30 |
PMC |
N |
PMC7102735 |
27095301.0 |
10.1016/j.jiph.2016.04.001 |
1a0fj900 |
0.380638 |
Sperber_1987 |
|
| 29 |
Morse_2020 |
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV |
Morse, Jared S.; Lalonde, Tyler; Xu, Shiqing; Liu, Wenshe Ray |
2020 |
2020-02-25 |
PMC |
N |
PMC7162020 |
32022370.0 |
10.1002/cbic.202000047 |
69toerzi |
0.377822 |
|
Omrani_2015 |
| 30 |
Weston_2020 |
FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro |
Stuart Weston; Rob Haupt; James Logue; Krystal Matthews; Matthew B. Frieman |
2020 |
2020-03-27 |
BioRxiv |
Y |
|
|
10.1101/2020.03.25.008482 |
jbc74lcu |
0.358539 |
Dove_2004, Ekins_2015, Beigel_2010 |
Jeon_2020 |
| 31 |
Elfiky_2017 |
Quantitative structure‐activity relationship and molecular docking revealed a potency of anti‐hepatitis C virus drugs against human corona viruses |
Elfiky, Abdo A.; Mahdy, Samah M.; Elshemey, Wael M. |
2017 |
2017-02-16 |
PMC |
N |
PMC7167072 |
27864902.0 |
10.1002/jmv.24736 |
nit5v1wg |
0.350044 |
|
|
| 32 |
Mahapatra_2020 |
Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking |
Sovesh Mahapatra; Prathul Nath; Manisha Chatterjee; Neeladrisingha Das; Deepjyoti Kalita; Partha Roy; Soumitra Satapathi |
2020 |
2020-04-07 |
BioRxiv |
Y |
|
|
10.1101/2020.04.05.20054254 |
m0q7rm6z |
0.347967 |
Dove_2004 |
Lv_B_2018, Li_Y_2020, Tang_2020 |
| 33 |
Bernini_2006 |
Tertiary structure prediction of SARS coronavirus helicase |
Bernini, Andrea; Spiga, Ottavia; Venditti, Vincenzo; Prischi, Filippo; Bracci, Luisa; Huang, Jiandong; Tanner, Julian A.; Niccolai, Neri |
2006 |
2006-05-19 |
PMC |
N |
PMC7092897 |
16579970.0 |
10.1016/j.bbrc.2006.03.069 |
ex3vep1z |
0.341580 |
|
|
| 34 |
Gordon_2020 |
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing |
David E. Gordon; Gwendolyn M. Jang; Mehdi Bouhaddou; Jiewei Xu; Kirsten Obernier; Matthew J O'Meara; Jeffrey Z. Guo; Danielle L. Swaney; Tia A. Tummino; Ruth Huttenhain; Robyn Kaake; Alicia L. Richards; Beril Tutuncuoglu; Helene Foussard; Jyoti Batra; Kelsey Haas; Maya Modak; Minkyu Kim; Paige Haas; Benjamin J. Polacco; Hannes Braberg; Jacqueline M. Fabius; Manon Eckhardt; Margaret Soucheray; Melanie Brewer; Merve Cakir; Michael J. McGregor; Qiongyu Li; Zun Zar Chi Naing; Yuan Zhou; Shiming Peng; Ilsa T. Kirby; James E. Melnyk; John S Chorba; Kevin Lou; Shizhong A. Dai; Wenqi Shen; Ying Shi; Ziyang Zhang; Inigo Barrio-Hernandez; Danish Memon; Claudia Hernandez-Armenta; Christopher J.P. Mathy; Tina Perica; Kala B. Pilla; Sai J. Ganesan; Daniel J. Saltzberg; Rakesh Ramachandran; Xi Liu; Sara B. Rosenthal; Lorenzo Calviello; Srivats Venkataramanan; Yizhu Lin; Stephanie A. Wankowicz; Markus Bohn; Phillip P. Sharp; Raphael Trenker; Janet M. Young; Devin A. Cavero; Joseph Hiatt; Theo Roth; Ujjwal Rathore; Advait Subramanian; Julia Noack; Mathieu Hubert; Ferdinand Roesch; Thomas Vallet; Björn Meyer; Kris M. White; Lisa Miorin; Oren S. Rosenberg; Kliment A. Verba; David Agard; Melanie Ott; Michael Emerman; Davide Ruggero; Adolfo Garcí-Sastre; Natalia Jura; Mark von Zastrow; Jack Taunton; Olivier Schwartz; Marco Vignuzzi; Christophe d'Enfert; Shaeri Mukherjee; Matt Jacobson; Harmit S. Malik; Danica G Fujimori; Trey Ideker; Charles S Craik; Stephen Floor; James S. Fraser; John Gross; Andrej Sali; Tanja Kortemme; Pedro Beltrao; Kevan Shokat; Brian K. Shoichet; Nevan J. Krogan |
2020 |
2020-03-22 |
BioRxiv |
Y |
|
|
10.1101/2020.03.22.002386 |
38d6gb7o |
0.334568 |
|
|
| 35 |
Mustafa_2018 |
Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review |
Mustafa, Sabeena; Balkhy, Hanan; Gabere, Musa N. |
2018 |
2018-02-28 |
PMC |
N |
PMC7102797 |
28864360.0 |
10.1016/j.jiph.2017.08.009 |
r88zb7t4 |
0.334511 |
Li_C_2019, Dove_2004, Beigel_2010, Wisskirchen_2014 |
Omrani_2015, Al-Tawfiq_2016 |
| 36 |
Jin_Z_2020 |
Structure of Mpro from COVID-19 virus and discovery of its inhibitors |
Zhenming Jin; Xiaoyu Du; Yechun Xu; Yongqiang Deng; Meiqin Liu; Yao Zhao; Bing Zhang; Xiaofeng Li; Leike Zhang; Chao Peng; Yinkai Duan; Jing Yu; Lin Wang; Kailin Yang; Fengjiang Liu; Rendi Jiang; Xinglou Yang; Tian You; Xiaoce Liu; Xiuna Yang; Fang Bai; Hong Liu; Xiang Liu; Luke W. Guddat; Wenqing Xu; Gengfu Xiao; Chengfeng Qin; Zhengli Shi; Hualiang Jiang; Zihe Rao; Haitao Yang |
2020 |
2020-02-27 |
BioRxiv |
Y |
|
|
10.1101/2020.02.26.964882 |
wx7nheay |
0.334307 |
Shaw_2011, Pizzorno_2019, Martínez_2008 |
Rut_W_2020, Zhou_2011 |
| 37 |
Sheahan_2020 |
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus |
Timothy P. Sheahan; Amy C. Sims; Shuntai Zhou; Rachel L. Graham; Collin S. Hill; Sarah R. Leist; Alexandra Schäfer; Kenneth H. Dinnon; Stephanie A. Montgomery; Maria L. Agostini; Andrea J. Pruijssers; James D. Chapell; Ariane J. Brown; Gregory R. Bluemling; Michael G. Natchus; Manohar Saindane; Alexander A. Kolykhalov; George Painter; Jennifer Harcourt; Azaibi Tamin; Natalie J. Thornburg; Ronald Swanstrom; Mark R. Denison; Ralph S. Baric |
2020 |
2020-03-20 |
BioRxiv |
Y |
|
|
10.1101/2020.03.19.997890 |
t5iz3vdz |
0.331751 |
|
|
| 38 |
Xu_J_2020 |
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |
Xu, Jimin; Shi, Pei-Yong; Li, Hongmin; Zhou, Jia |
2020 |
2020-03-03 |
PMC |
Y |
PMC7098069 |
32125140.0 |
10.1021/acsinfecdis.0c00052 |
ju35nyir |
0.330019 |
Pizzorno_2019, Martínez_2008 |
Zhu_X_2015, Blaising_2014, D’Alessandro_2020 |
| 39 |
Choudhary_2020 |
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance |
Choudhary, Renuka; Sharma, Anil K.; Choudhary, Renuka |
2020 |
2020-04-22 |
PMC |
Y |
|
|
10.1016/j.nmni.2020.100684 |
tqj2s9qf |
0.327535 |
|
|
| 40 |
Rut_W_2020 |
Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design |
Wioletta Rut; Katarzyna Groborz; Linlin Zhang; Xinyuanyuan Sun; Mikolaj Zmudzinski; Rolf Hilgenfeld; Marcin Drag |
2020 |
2020-03-08 |
BioRxiv |
Y |
|
|
10.1101/2020.03.07.981928 |
e8qubwha |
0.327115 |
Pizzorno_2019, Shaw_2011 |
Adhikari_2017, Zhu_X_2015 |
| 41 |
de_Wit_2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection |
de Wit, Emmie; Feldmann, Friederike; Cronin, Jacqueline; Jordan, Robert; Okumura, Atsushi; Thomas, Tina; Scott, Dana; Cihlar, Tomas; Feldmann, Heinz |
2020 |
2020-03-24 |
COMM-USE |
Y |
PMC7104368 |
32054787.0 |
10.1073/pnas.1922083117 |
x50tvq3a |
0.326748 |
|
de_Wit_2018, Omrani_2015 |
| 42 |
Haagmans_2006 |
Coronaviruses and their therapy |
Haagmans, Bart L.; Osterhaus, Albert D.M.E. |
2006 |
2006-09-30 |
PMC |
N |
PMC7114240 |
16837072.0 |
10.1016/j.antiviral.2006.05.019 |
j0496jb7 |
0.318890 |
|
Adedeji_2014 |
| 43 |
Chen_2004 |
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds |
Chen, F; Chan, K.H; Jiang, Y; Kao, R.Y.T; Lu, H.T; Fan, K.W; Cheng, V.C.C; Tsui, W.H.W; Hung, I.F.N; Lee, T.S.W; Guan, Y; Peiris, J.S.M; Yuen, K.Y |
2004 |
2004-09-30 |
PMC |
N |
PMC7128415 |
15288617.0 |
10.1016/j.jcv.2004.03.003 |
ot5pvtbl |
0.316654 |
Sperber_1987, Wang_2016 |
|
| 44 |
Ortega_2020 |
Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target |
Ortega, Joseph Thomas; Serrano, Maria Luisa; Pujol, Flor Helene; Rangel, Hector Rafael |
2020 |
2020-03-17 |
COMM-USE |
Y |
PMC7081067 |
|
10.17179/excli2020-1189 |
qdt90c22 |
0.313822 |
|
Adhikari_2017 |
| 45 |
Caly_2020 |
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
Caly, Leon; Druce, Julian D.; Catton, Mike G.; Jans, David A.; Wagstaff, Kylie M. |
2020 |
2020-06-30 |
PMC |
Y |
|
|
10.1016/j.antiviral.2020.104787 |
ivy95jpw |
0.311775 |
Beigel_2010, Shaw_2011, García-Serradilla_2019 |
Tan_E_2004 |
| 46 |
Pereira_2020 |
Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review |
Pereira, Boscolli Barbosa |
2020 |
2020-04-12 |
PMC |
Y |
PMC7157945 |
32281481.0 |
10.1080/10937404.2020.1752340 |
jk62qn0z |
0.310461 |
van_Boven_2008, Beigel_2010 |
|
| 47 |
Sharma_2020 |
Chloroquine paradox may cause more damage than help fight COVID-19 |
Sharma, Anuj |
2020 |
2020-04-17 |
PMC |
Y |
|
|
10.1016/j.micinf.2020.04.004 |
j9vmsfjw |
0.310078 |
Beigel_2010 |
|
| 48 |
Mestres_2020 |
The target landscape of N4-hydroxycytidine based on its chemical neighborhood |
Jordi Mestres |
2020 |
2020-04-01 |
BioRxiv |
Y |
|
|
10.1101/2020.03.30.016485 |
yzrni12u |
0.308824 |
Dove_2004 |
Zhu_X_2015 |
| 49 |
Riva_2020 |
A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals |
Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda |
2020 |
2020-04-17 |
BioRxiv |
Y |
|
|
10.1101/2020.04.16.044016 |
1fgnfh62 |
0.308824 |
Beigel_2010, Shaw_2011 |
|
| 50 |
Wu_C_2020 |
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |
Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua |
2020 |
2020-01-01 |
None |
Y |
|
|
10.1016/j.apsb.2020.02.008 |
b31ctbat |
0.307065 |
|
Adhikari_2017, Su_H_2020 |
| 51 |
Dyall_2017 |
Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies |
Dyall, Julie; Gross, Robin; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Hensley, Lisa E.; Frieman, Matthew B.; Jahrling, Peter B. |
2017 |
2017-12-23 |
None |
N |
PMC5733787 |
29143192.0 |
10.1007/s40265-017-0830-1 |
hyihoelf |
0.304138 |
Dove_2004, Beigel_2010 |
Al-Tawfiq_2016, Mustafa_2018, Omrani_2015 |
| 52 |
Ge_Y_2020 |
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 |
Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng |
2020 |
2020-03-12 |
BioRxiv |
Y |
|
|
10.1101/2020.03.11.986836 |
qebbkr6d |
0.301764 |
|
Tang_2020, Xing_2020 |